ACOTEC-B (06669) announced its 2025 financial performance, achieving revenue of approximately 645 million yuan, representing a year-on-year increase of 20.7%. Gross profit reached about 476 million yuan, up 18.3% compared to the previous year. Annual profit amounted to roughly 119 million yuan, marking a significant growth of 128%. Basic earnings per share were 0.4 yuan.

The year 2025 represented a harvest period for product approvals, as the synergistic effects of the company's mature and diversified R&D technology portfolio yielded results. During the reporting period, the company secured registration approvals from the National Medical Products Administration and the Beijing Medical Products Administration for a total of 11 products. Several of these products signified milestone launches for the company.

Concurrently, the company continued to expand its global footprint. It completed the registration or filing for its peripheral drug-coated balloon (DCB) products in seven new countries. Furthermore, the company's peripheral radiofrequency ablation system, AcoArt Cedar®, received 510(k) clearance from the U.S. FDA in October 2025.

Regarding commercialization in Mainland China, the company has established a robust sales and marketing team alongside an extensive distribution network. Its commercial products now cover over 3,000 hospitals. In overseas markets, BSC Group has achieved active sales for distributed collaborative products across 17 countries globally.